on Heidelberg Pharma AG (isin : DE000A11QVV0)
Heidelberg Pharma Reports 2024 Financial Results and Clinical Progress
Heidelberg Pharma AG has released its financial figures for 2024, highlighting significant milestones. Notably, one patient in the HDP-101 clinical trial for multiple myeloma achieved complete remission. This underlines the potential of Heidelberg's ADC technology as a cancer therapy. Additionally, HDP-102 trials targeting non-Hodgkin lymphoma are set to commence.
Financially, the company saw improved results, driven by a USD 20 million payment from HealthCare Royalty, extending their cash runway. Despite a decrease in annual revenues to EUR 12.0 million from EUR 16.8 million, operating expenses fell significantly.
Looking forward, the firm anticipates income between EUR 9.0 million and EUR 11.0 million for 2025, with continued investment in key projects facilitated by strategic financial agreements.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Heidelberg Pharma AG news